GlassScriptPhysician profile
Shency Varughese
NPI 1598207375
$4,467.96
in general payments reported to CMS, 2019-2025
29 companies · $933 in 2025
The $933 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $287 · 2023: $962 · 2024: $1,896 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,255.12 | 2021-2025 | Enhertu, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $380.19 | 2022-2025 | Reblozyl, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $333.46 | 2021-2025 | Entyvio, Fruzaqla |
| Abbvie INC. | $281.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $274.23 | 2022-2025 | Keytruda, Lynparza, Dificid |
| Novartis Pharmaceuticals Corporation | $227.03 | 2023-2025 | |
| Syndax Pharmaceuticals, INC. | $174.86 | 2025 | Revuforj |
| Lilly USA, LLC | $157.34 | 2023-2024 | Verzenio, Jaypirca, Cyramza |
| Madrigal Pharmaceuticals | $141.60 | 2025 | Rezdiffra |
| Legend Biotech USA INC. | $132.56 | 2025 | Carvykti |
| Incyte Corporation | $118.75 | 2024 | Jakafi |
| Daiichi Sankyo INC. | $105.77 | 2023 | Enhertu |
| Pharmaessentia USA Corporation | $100.00 | 2025 | Besremi |
| Seagen INC. | $94.11 | 2022-2023 | Tivdak, Padcev |
| Astellas Pharma US INC | $92.73 | 2023-2024 | Xtandi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.58 | 2024 | |
| Exelixis INC. | $76.26 | 2022 | |
| Genentech USA, INC. | $71.28 | 2021 | |
| Pfizer INC. | $62.22 | 2024 | |
| Digestive Care, INC. | $58.76 | 2024-2025 | Pertzye |
| Blueprint Medicines Corporation | $46.99 | 2023-2024 | Ayvakit |
| Janssen Biotech, INC. | $35.69 | 2024 | Rybrevant |
| Glaxosmithkline, LLC. | $26.90 | 2024 | Jemperli, Zejula |
| Eisai INC. | $24.49 | 2023 | |
| Biogen, INC. | $24.39 | 2025 | Zurzuvae |
| Ultragenyx Pharmaceutical INC. | $22.47 | 2024 | Crysvita |
| Vivus LLC | $21.91 | 2025 | Qsymia |
| Paratek Pharmaceuticals, INC. | $19.86 | 2024 | Nuzyra |
| Servier Pharmaceuticals LLC | $15.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shency Varughese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.